Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

DSM Announces Biologics Development and Manufacturing Agreement for Australian Facility

Published: Thursday, October 25, 2012
Last Updated: Thursday, October 25, 2012
Bookmark and Share
DSM has signed a biologics contract manufacturing agreement with Paranta Biosciences.

DSM Pharmaceutical Products has announced that it has signed a biologics contract manufacturing agreement with Paranta Biosciences Ltd of Melbourne, Australia.

The contract covers the process development and cGMP manufacture by DSM of Paranta's lead recombinant human protein. This project represents an agreement for DSM with an Australian customer at their Brisbane facility.

Paranta Biosciences is an early stage drug development company dedicated to developing and commercializing novel biotherapeutics based on recombinant human follistatin for the treatment of respiratory diseases.

Alexander Wessels, CEO of DSM Pharmaceutical Products, stated, "Working with Paranta is an important milestone for DSM to support the local client base directly from our facility in Australia, expanding our presence in global regions. Our collaboration with Biopharmaceuticals Australia (BPA), the Queensland Government and the Australian Commonwealth Government is already bringing benefits to Australia by providing biopharmaceutical firms local support and manufacturing expertise."

Ross Barrow, CEO of Paranta Biosciences stated, "Follistatin has been shown to have great potential in treating a wide range of inflammatory and fibrotic respiratory diseases, which affect over 300 million people worldwide. Our selection of DSM as Paranta's biologics manufacturing partner is the culmination of an extensive global search process spanning more than nine months. We are looking forward to working with the Groningen and Brisbane groups of DSM Biologics as we continue the development and manufacturing scale-up of what we believe will be a truly exciting biotherapeutic."

Karen King, President of DSM Biologics, the business unit of DSM Pharmaceutical Products operating the Brisbane site, commented "We are proud to announce that Paranta has selected DSM as its manufacturing and development provider. DSM will bring over 25 years of experience, a state-of-the-art facility and an expert team in Brisbane to help drive the success of Paranta's lead project."

In addition to an R&D and manufacturing site in Groningen, The Netherlands, DSM is building operations in Brisbane, Australia, with the support of the Governments of Queensland and the Commonwealth.

The Brisbane facility is DSM's blueprint for its 'biologics plant of the future' for the production of biopharmaceuticals.

"For Biopharmaceuticals Australia, DSM's signing-up Paranta for the new facility represents a key endorsement of the wisdom of the public sector investment in the project." said CEO, David Hughes.

"The Paranta contract is an important step in ensuring that more of the drug development value chain is retained locally". BPA, an industry-development company owned by the Queensland State Government, put together the partnering deal with DSM, and is currently project managing the final stages of the construction of the new state-of-the-art facility in cooperation with DSM Biologics."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DSM and Opthea Sign Agreement
Agreement to manufacture Opthea’s lead product for eye disease.
Wednesday, October 30, 2013
DSM and DecImmune Therapeutics Sign Agreement
Agreement to develop N2 pathway blocking antibody.
Monday, April 22, 2013
PolyTherics Moves Lead Candidate into Development and Manufacturing with DSM BioSolutions
Both the companies have entered into an agreement for the process development and manufacture of PolyTherics’ lead biobetter product, HiPEG™ IFN a-2a.
Friday, September 10, 2010
Scientific News
2015 ACS GCI Pharmaceutical Roundtable Research Grant
Request for proposals: Greener Continuous Chemistry & Engineering Technology.
'Crumpled' Filter to Slash Energy Consumption
Scientists have developed an ultra-thin, super-strong membrane to filter liquids and gases, with the potential to cut energy consumption in industry.
Tackling Chemical Safety Rules and Regulations
Helsinki Chemicals Forum continues to lead international chemicals safety and management discussions.
Pioneering New Method to Map Enzyme Activity
Cardiff University researchers new discovery could have wide-reaching implications for the creation of manufactured goods, biofuels and therapeutic drugs.
Euro Vision turns Reality for Australia’s Iconic ‘Green Whistle’
Patients will soon benefit from a unique invention, with emergency pain killer Penthrox receiving initial regulatory approval for sale in the European and UK markets.
Gaining the Full Benefit of Microflow Electrolysis Cells
This paper sets out the factors that should be considered in seeking good performance from microflow cells for organic electrosynthesis.
Are Chemical Safety Regulations Changing Your Laboratory?
GHS changes to country chemical regulations affect everyone.
Continuous Flow of Breakthroughs for Vapourtec
Flow chemistry systems designed and manufactured by Vapourtec have recently reached the milestone of having been cited in 150 peer review publications.
A Continuous Flow System for the Measurement of Ambient Nitrogen Oxides
The proposed method can be used in industrial locations to continuously monitor ambient NOx levels and it can be automated for measuring the variation of NOx concentrations.
Accelerating Spirocyclic Polyketide Synthesis
Powerful flow chemistry techniques used for complex multi-stage synthesis of spirocyclic polyketides.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!